with acute myelogenous leukemia (AML). 1,2 However, most will relapse despite consolidation and maintenance chemotherapy. Therefore, post-remission therapy is one of The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transthe most important issues in the treatment of AML. An increasing number of AML patients have been treated with plantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood intensified consolidation chemotherapy, autologous bone marrow transplantation (BMT), or allogeneic BMT. ditioning regimen and graft-versus-leukemia (GVL) effects. 5 Nevertheless, in addition to the requirement of was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-HLA-identical marrow donors, transplant-related morbidity and mortality remain the major obstacles to improving stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning.
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with acute myelogenous leukemia (AML). 1,2 However, most will relapse despite consolidation and maintenance chemotherapy. Therefore, post-remission therapy is one of The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transthe most important issues in the treatment of AML. An increasing number of AML patients have been treated with plantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood intensified consolidation chemotherapy, autologous bone marrow transplantation (BMT), or allogeneic BMT. 3, 4 Allostem cells (PBSC) were collected during recovery after consolidation chemotherapy. High-dose chemotherapy geneic BMT is most successful for reducing leukemic relapse by virtue of the high-dose chemoradiotherapy conconsisting of busulfan (16 mg/kg), etoposide (40 mg/kg), and cytosine arabinoside (3 g/m 2 × 4) (BEA regimen) ditioning regimen and graft-versus-leukemia (GVL) effects. 5 Nevertheless, in addition to the requirement of was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-HLA-identical marrow donors, transplant-related morbidity and mortality remain the major obstacles to improving stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning.
clinical results of allogeneic BMT. In autologous BMT, regimen-related toxicities are fewer, although a GVL effect Unpurged, cryopreserved PBSC containing a median number of 5.4 × 10 8 MNC/kg or 12 × 10 4 CFU-GM/kg cannot be obtained. One randomized study has demonstrated that patients treated with autologous BMT have were reinfused at transplantation. The median number of days to granulocytes exceeding 500/l and last platesuperior disease-free survivals (DFS) to those receiving intensive chemotherapy alone.
3 let transfusion were 15 (8-44) and 24 (0-Ͼ180), respectively. The 3-year probabilities of disease-free survival Recently, autologous peripheral blood stem cell transplantation (ABSCT) has begun to replace autologous BMT (DFS) and relapse were 78.6 and 21.4% for patients transplanted in first remission, 29.6 and 64.4% for those because of rapid engraftment and low transplant-related mortality. [6] [7] [8] [9] [10] [11] However, high relapse rates have been in second or third remission, and 11.1 and 77.8% for those in relapse, respectively. There were no transplantreported after ABSCT for AML. CR = complete remission; G-CSF = granulocyte colony-stimulating factor; BEA = busulfan 16 mg/kg orally, etoposide 40 mg/kg intravenously, and cytosine arabinoside 3 g/m 2 intravenously every 12 h for 2 days; ABSCT = autologous peripheral blood stem cell transplantation; MNC = mononuclear cells; CFU-GM = colony-forming unit granulocyte-macrophage.
Chemotherapy and collection of peripheral blood stem
Consolidation chemotherapy consisting of Ara-C 500 mg/m 2 intravenously every 12 h for 6 days combined cells (PBSC) with mitoxantrone 7 mg/m 2 intravenously for 3 days in the Figure 1 shows the treatment protocol used in this study.
first course and etoposide 100 mg/m 2 intravenously for 5 Induction chemotherapy for all but AML/M3 patients condays in the second course, was begun after achieving comsisted of daunorubicin (DNR) 45 mg/m 2 intravenously for plete remission. 14 Collection of PBSC was performed with 3 days and cytosine arabinoside (Ara-C) 100 mg/m 2 by cona continuous blood-cell separator during hemopoietic tinuous infusion for 7 days. Bone marrow aspiration was perrecovery after each round of consolidation chemotherapy formed on day 8, and if the marrow was not severely hypoplwith or without G-CSF (filgrastim, 200 g/m 2 intraastic, DNR was added on days 8 and 9, and Ara-C venously). Unpurged PBSC harvests were cryopreserved by administration was continued for 3 more days (days 8, 9 and a simplified method without rate-controlled freezing until 10). For AML/M3 patients, all-trans retinoic acid was admintransplantation. 15 Granulocyte-macrophage progenitor cells istered according to the protocol described elsewhere. in each PBSC harvest were assayed as described preResults viously.
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Hemopoietic recovery after ABSCT
No patient had engraftment failure. The median number of days to granulocytes exceeding 500/l was 15 (range 8-ABSCT 44), which was not affected by G-CSF administration after ABSCT ( Figure 2 ). The speed of granulocyte recovery was The pretransplant conditioning regimen for 13 patients coninversely correlated with the number of CFU-GM infused sisted of busulfan 4 mg/kg orally on days −8 to −5, etopo-(r = 0.415). Granulocytes exceeded 500/l within 14 days side 20 mg/kg intravenously on days −4 and −3, and Araafter transplantation in 21 of 37 patients (57%) who were C 3 g/m 2 intravenously every 12 h on days −3 and −2 (BEA autografted with more than 0.5 × 10 5 CFU-GM/kg, and in regimen). For the remaining 47 AML patients, G-CSF was 18 of 27 patients (67%) with more than 1.0 × 10 5 CFUcombined with the BEA regimen to increase the chemo-GM/kg. The median time to the last platelet transfusion was sensitivity of leukemic cells to the S-phase-specific anti-24 days (range 0-Ͼ180) (Figure 2 ). Prophylactic platelet leukemic agent, Ara-C. G-CSF was administered at a dose transfusions were given to maintain platelet counts above of 5 g/kg on days −14 to −8, 10 g/kg on days −7 and 2 × 10 4 /l. Platelet recovery was also inversely correlated −6, and 20 g/kg on days −5 and −4 by 6-h intravenous with the number of CFU-GM infused (r = −0.409). Howinfusion in combination with continuous infusion of Araever, 13 of 60 patients (22%) continued to be dependent C 100 mg/m 2 on days −12 to −6, in addition to the above on platelet transfusion for more than 3 months, and seven BEA regimen. 16, 17 One day later, cryopreserved PBSC were of these 13 patients (54%) relapsed within 5 months of rapidly thawed in a 37°C waterbath and infused through a transplantation. central venous catheter without washing on day 0. If a sufficient number of CFU-GM had been obtained at the second Treatment outcome PBSC collection (CFU-GM у1 × 10 5 /kg), the second PBSC harvest was used instead of the first harvest for transOf 60 patients with AML, 42 received ABSCT in first remission, nine in second or third remission, and nine in plantation. G-CSF 200 g/m 2 was administered intrarelapse. Among the nine patients transplanted in second or venously from day 1 until full recovery of granulocytes in third remission, PBSC collection was done during the first 18 of 60 patients. Complications related to the pretransplant remission in two, during the second in six, and during the conditioning were classified according to the criteria prothird in one. In all relapsed patients receiving ABSCT, posed by Bearman et al. 18 PBSCs were harvested during first remission.
The 3-year and 5-year probabilities of DFS for patients transplanted in first remission were 78.6 and 70.7%, respectively ( Figure 3) . The median survival time for these Statistical analysis patients without relapse was 17 months (range 4-73 months). Nine patients relapsed, eight (89%) within A linear regression analysis was employed for evaluating 12 months of transplantation. The median interval from relationships between numbers of CFU-GM infused and the remission to ABSCT was 5 months (range 3-13 months) speed of hemopoietic recovery after transplantation. 19 Disfor patients who had transplants in first remission. The 5-tributions of achieving granulocytes Ͼ500/l, achieving year DFS probability for 20 patients autografted more than platelet transfusion independency, DFS, and relapse were 6 months after remission was 90.0%, compared with 43.5% estimated by the product-limit method. 20 Comparisons of for 22 patients who had transplants before 6 months. This these results were based on the log-rank test. DFS was condifference was statistically significant (P Ͻ 0.05 by logsidered as the time from transplant to relapse or death due rank test). Of 42 patients autografted in first remission, 17 to any cause. Actuarial curves were analyzed as of 1 Nov-(40.5%) had favorable cytogenetics. The 5-year DFS probember 1996. Cox's regression analysis in a stepwise manner was performed to determine prognostic factors with regard to DFS. 21 Factors used in this analysis included gender, age (Ͻ40 vs у40 years), WBC count at diagnosis (Ͻ20 000/ vs у20 000/l), FAB subtype (M2 or M3 vs M1, M4, M5 or M6), karyotype (favorable vs all others), number of induction chemotherapy cycles to remission (1 course vs у2 courses), G-CSF administration for PBSC mobilization (yes vs no), G-CSF administration after transplantation (yes vs no), disease status at transplantation (first remission vs beyond first remission), and pretransplant conditioning (G-CSF combined BEA vs non-G-CSF combined BEA). Analysis was carried out using a statistical package, BMDP 2L, on an IBM system 3090 computer. G-CSF administration for PBSC mobilization or after transplantation, and pretransplant conditioning, did not affect the outcome of ABSCT for AML.
Toxicities
Oral mucositis and gastrointestinal symptoms such as nausea, vomiting, and diarrhea, were common toxicities related to the BEA or G-CSF combined BEA regimen. The incidence of regimen-related toxicities greater than grade II Years after ABSCT Probability of DFS (%) was as follows: oral toxicity, 23%; gastrointestinal toxicity, Figure 3 Kaplan-Meier estimates of DFS for AML patients transplanted 7%; hepatic toxicity, 3%; and cardiac toxicity, 7%. There in first remission (--, n = 42), in second or third remission (-----, n = 9), was no early transplant-related mortality (within 100 days). abilities for those with favorable cytogenetics and for the remaining 25 patients were 93.3 and 55.6%, respectively Discussion (P = 0.06 by log-rank test).
The 3-year probabilities of DFS for patients autografted The present study confirmed rapid granulocyte recovery in second or third remission, and in relapse were 29.6 and and low transplant-related mortality in patients with AML 11.1%, respectively ( Figure 3) . Two of nine patients transtreated with myeloablative chemotherapy and ABSCT. Plaplanted in second or third remission and one of nine telet recovery was slightly delayed; 13 of 60 patients (22%) patients in relapse are alive in complete remission. required platelet transfusions for more than 3 months. The 3-year probability of relapse for AML patients transBecause the speed of hemopoietic recovery is inversely corplanted in first remission was 21.4% ( Figure 4) . In contrast, related with the number of PBSC infused, 14 this delay was the 3-year probabilities of relapse for patients transplanted probably due to the relatively low numbers of CFU-GM in second or third remission and in relapse were 64.4 and infused as compared to other studies. 7 Early relapse was 77.8%, respectively. Differences in relapse rates were sigobserved in seven of these 13 patients, another factor which nificant between patients autografted in first remission vs may have delayed platelet recovery. The remaining six second or third remission, and between those in first patients are alive without relapse and eventually became remission vs relapse (P Ͻ 0.01 for both).
independent of platelet transfusions. There was no transplant-related mortality within Prognostic factors 100 days after transplantation in our study, although early severe hepatic toxicity developed in one patient who was Multivariate analyses revealed that age, disease status at autografted in second remission. Fatal VOD in this patient transplantation, and the number of induction chemomay have been related to the repeated intensive chemotherapies to first complete remission were significant risk therapy prior to transplantation. An increased incidence of factors influencing DFS (Table 2) . AML patients who were VOD has been linked to pretransplant conditioning with younger than 40 years old, autografted in first remission, busulfan in allogeneic BMT. 22, 23 Sanz et al 9 similarly and achieved first remission with only one course of inducreported fatal VOD in two of 24 patients who received tion chemotherapy, showed better DFS. Factors such as ABSCT for AML using a busulfan-containing regimen. The gender, WBC count at diagnosis, FAB subtype, karyotype, use of busulfan in these patients needs to be evaluated in prospective studies. ABSCT has several advantages over autologous BMT, including rapid engraftment and low transplant-related mortality. However, the collective data indicate that relapse rates are as high as 60% after ABSCT for AML, 6,9,10 and early relapse is frequent. 7, 8 This may occur because the ratio of leukemic clonogenic progenitors to normal stem cells is higher in PBSC harvests than in marrow 8 or because a large number of malignant cells are reinfused since the cell dose is higher in ABSCT than in autologous BMT. 7 However, a retrospective study has demonstrated that the risk of relapse and the likelihood of disease-free survival Years after ABSCT Probability of relapse (%) after ABSCT for AML are similar to those seen after auto- and that the use of PBSC was not associated with an containing intermediate-dose Ara-C in the present study may be responsible for in vivo purging. increased risk of relapse.
AML patients transplanted in first remission had a favorLastly, intensification of pretransplant conditioning by cytokine priming may have improved DFS in our study. Gable DFS in our study. The 5-year probability of DFS was more than 70%. Possible explanations include a low inci-CSF can stimulate the proliferation of myeloid leukemic cells because most express receptors for G-CSF. 29 An dence of transplant-related mortality which may contribute to DFS. Although we did not encounter engraftment failure increased susceptibility of leukemic cells to Ara-C in the presence of G-CSF has been demonstrated in vitro. 17 Moreor early transplant-related mortality, most studies have reported the incidence of transplant-related mortality to be over, clinical studies support a potential role for G-CSF in the pretransplant conditioning regimen to reduce leukemic 5-10%. 6, 9, 25 In addition, patient selection may have affected the outcome of our study, since 22 of 42 patients (52.4%) relapses after ABSCT or allogeneic BMT. 16, 17 A prospective randomized study will be required to assess further the autografted in first remission were classified as M2 or M3 and 17 of these (40.5%) had favorable cytogenetics such efficacy of G-CSF priming for pretransplant conditioning. There are few reports describing the prognostic factors as t(8;21), t(15;17), or inv (16); the proportion of patients with these subtypes is higher than in other studies. 6, 9 Howfor DFS and relapse after ABSCT for AML. Korbling et al 6 have suggested that FAB M5 is a prognostic factor. In ever, multivariate analyses did not indicate that FAB subtype or karyotype were significant factors for DFS. In a autologous BMT, on the other hand, a WBC Ͼ50 000/l at diagnosis, the need for more than two courses of induction recent report by Mehta et al, 7 AML patients treated with ABSCT with biphenotypic or dysplastic features often had chemotherapy to achieve remission, and certain cytogenetic findings have been shown to be adverse prognostic facearly relapse; although such patients were not included in the present study, three other patients with biphenotypic tors. 3, 25 In the present study, age, disease status at transplantation, and the number of induction courses to achieve leukemia who received ABSCT at our institution relapsed soon after transplantation (data not shown). Therefore, the remission affected DFS, indicating that younger patients (Ͻ40 years old) with AML who achieved complete biologic characteristics of the leukemic cells should be considered as a potent prognostic factor for ABSCT.
remission after one course of induction therapy may benefit from ABSCT during the first remission. The timing of PBSC collection may also be important for preventing relapse. Recently, we demonstrated that minimal In summary, the present clinical study has demonstrated the safety and efficacy of myeloablative chemotherapy folresidual disease (MRD) in marrow and PBSC harvests could be reduced with repeated chemotherapy. 26, 27 Based lowed by ABSCT for the treatment of AML. Although the number of patients was small and follow-up time was short, upon these data, we collected PBSC not after induction chemotherapy, but instead during the recovery phase after the encouraging results obtained with this study warrant additional prospective studies to evaluate the use of consolidation. 9, 10 Furthermore, when PBSC harvests after a second consolidation course contained sufficient numbers ABSCT in the treatment of AML. of PBSC, we preferentially used that harvest because it potentially contained fewer leukemic cells than the harvest after the first consolidation course. This strategy of in vivo Acknowledgements purging has been used to reduce the leukemic burden in the setting of autologous BMT and has led to an improved This work was supported in part by grants-in-aid from the Minis-DFS.
25, 28 Mehta et al 28 important factor associated with continuing remission after autologous BMT. Stein et al 25 have conducted a prospective study of autologous BMT for AML in first remission, in which marrow was collected after consolidation chemoReferences therapy containing high-dose Ara-C. They demonstrated that the probabilities of DFS at 24 months were 49% in the
